Please sign in to follow a disease.
Neurodermatitis
MONDO:0006585Skin findings arising from repeated rubbing, picking or scratching of a real or imagined irritation of the skin.
Also known as: lichen simplex Chronicus
11 clinical trials for this condition and its sub-types, 10 tagged with Neurodermatitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New shot could tame uncontrollable itch of prurigo nodularis
Disease control CompletedThis study tested the drug dupilumab in 151 adults with prurigo nodularis, a condition causing intense itching and raised skin bumps. Participants had severe itch that creams could not control. They received either dupilumab injections or a placebo for 24 weeks. The main goal was…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC
-
New hope for chronic itch: dupilumab tackles prurigo nodularis
Disease control CompletedThis study tested the drug dupilumab in 160 adults with prurigo nodularis, a skin condition causing intense itching and bumps. Participants received either dupilumab injections or a placebo for up to 24 weeks. The main goal was to see if dupilumab could reduce itch by at least 4 …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
Can an eczema drug stop the itch of lichen simplex chronicus?
Symptom relief CompletedThis Phase 3 trial tests whether dupilumab (Dupixent) can reduce severe itching in adults with lichen simplex chronicus, a skin condition causing intense itch. 142 participants will receive either dupilumab or placebo injections for 24 weeks. The main goal is to see if more peopl…
Phase 3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can an eczema drug stop the relentless itch of lichen simplex chronicus?
Symptom relief CompletedThis Phase 3 trial tests whether dupilumab (Dupixent) injections can reduce severe itching in adults with lichen simplex chronicus, a skin condition causing intense, persistent itch. About 138 participants will receive either dupilumab or a placebo for 24 weeks. The main goal is …
Phase 3 • Sponsor: Sanofi • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Shockwave therapy shows promise for relieving neurodermatitis itch
Symptom relief CompletedThis study tested whether extracorporeal shockwave therapy (ESWT) can reduce itching in people with neurodermatitis. Thirty-four adults aged 55 to 75 received four weekly sessions of shockwaves applied to the skin. The main goal was to measure changes in itch severity using a sta…
Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC